Dual CLL1/CD38 targeting CAR-T cell therapy (Gracell Biotechnologies)

N/A

Report date: 2025/06/23 16:49:09

Base Information

Drug NameDual CLL1/CD38 targeting CAR-T cell therapy (Gracell Biotechnologies)
Drug Alias NameCLL1 and CD38 dual-target CAR-T injection
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionLymphocyte differentiation antigen CD38 modulatorsC-Type lectin domain family 12 member A modulators
TargetsLymphocyte differentiation antigen CD38C-Type lectin domain family 12 member A
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGracell Biotechnologies (Shanghai) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca PlcGracell Biotechnologies (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A